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Peripheral Arterial Disease (PAD) is a cause of significant morbidity and mortality in the Western world. Risk factor modification
and endovascular and surgical revascularisation are the main treatment options at present. However, a significant number of
patients still require major amputation. There is evidence that nitric oxide (NO) and its endogenous inhibitor asymmetric
dimethylarginine (ADMA) play significant roles in the pathophysiology of PAD. This paper reviews experimental work implicating
the ADMA-DDAH-NO pathway in PAD, focussing on both the vascular dysfunction and eﬀects within the ischaemic muscle, and
examines the potential of manipulating this pathway as a novel adjunct therapy in PAD.
1. Introduction
Peripheral arterial disease (PAD) is a disorder characterised
by the progressive occlusion of the large- and medium-sized
arteries outside of the cardiopulmonary and cerebral vascu-
lar systems. It causes considerable morbidity and mortality,
aﬀecting over 2.7 million individuals in the Western world
[1] and most commonly manifests itself in the reduction of
blood flow to the lower limbs, which in severe cases lead to
chronic pain, gangrene, and eventually limb loss. Risk factors
include tobacco smoke, diabetes mellitus, hypertension, and
hypercholesterolaemia.
At amolecular level, dysfunction of the vascular endothe-
lium, in particular, disruption of the nitric oxide (NO)
pathway [2], plays a significant role. NO is a vasodilator
synthesized by the enzyme nitric oxide synthase (NOS) [3]
and has a number of important endocrine and paracrine
eﬀects, including reduction of vascular smooth muscle tone;
inhibition of platelet adhesion and aggregation; suppression
of inflammatory mediators; inhibition of smooth muscle
proliferation and migration; and promotion of endothelial
survival and repair [4].
There have been significant eﬀorts to elucidate the pa-
thophysiological role of the NO pathway in cardiovascular
diseases, with recent discoveries of endogenous NO inhib-
itors adding further complexity [5], but this has yet to be
translated into clinically significant therapies.
This paper aims to outline the current knowledge on NO
pathway dysfunction in PAD, including recent developments
in understanding the role of asymmetric dimethylarginine
(ADMA) and dimethylarginine dimethylaminohydrolase
(DDAH); it will also explore potential therapeutic strategies
based on the manipulation of this pathway.
2. The Nitric Oxide Pathway
NO is synthesised from L-arginine by NOS, of which there
are three isoforms [6]: NOS I or neuronal NOS (nNOS) was
originally isolated from rat and porcine cerebellum; NOS II
or inducible NOS (iNOS) from activated macrophages; NOS
III or endothelial NOS (eNOS) from endothelial cells.
All 3 NOS isoforms are competitively inhibited by
the methylarginines ADMA and monomethyl-arginine (L-
NMMA) which are by-products of protein degradation [7].
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Figure 1: The nitric oxide pathway.
Both ADMA and L-NMMA are predominantly broken down
by the enzyme DDAH into L-citrulline and dimethylamine
[8], of which there are two isoforms [9]: DDAH I, found
predominantly in tissues expressing NOS I, liver, kidney, and
lung; and DDAH II, found in tissues expressing NOS III and
NOS II, vascular endothelium, heart, placenta, and kidney.
Both isoforms have been found to be expressed in vascular
endothelium [9] (Figure 1).
ADMA’s role in vascular endothelial dysfunction was
first described by Vallance et al. in patients with end-stage
chronic renal failure, whose serum ADMA is raised due, in
part, to decreased renal clearance [10]. Further studies in
similar patients have shown a positive correlation between
ADMA levels and cardiovascular morbidity and mortality
[11]; whilst reduction of ADMA levels by renal dialysis helps
to restore endothelial function [12].
Other studies have demonstrated a correlation between
ADMA accumulation and cardiovascular risk as well as other
disease states [5]. Lu et al. showed that serum ADMA levels
have a positive correlation with the severity and extent
of coronary artery atherosclerosis [13]; Worthmann et al.
demonstrated a similar correlation between ADMA levels
and adverse prognosis in ischaemic stroke [14]; and ADMA
has been found to have significant roles in renal disease [15],
pulmonary artery hypertension [16], and erectile dysfunc-
tion [17].
The accumulation of ADMA and consequent endothelial
dysfunction, increased systemic vascular resistance, and in-
creased systemic blood pressure have been shown to be
due to reduced DDAH expression [18]. Upregulation of
DDAH I and DDAH II in human umbilical vein endothelial
cells (HUVECs) by adenoviral vectors leads to a fall in
ADMA and an increase in NO [7]. Similarly, upregulation of
DDAH I and II in DDAH I+/− mice was found to attenuate
the cardiovascular stress response, enhance acetylcholine-
mediated relaxation, and counteract the response to excess
ADMA; DDAH upregulation helps to reverse the cardiovas-
cular dysfunction inherented in these animals [7].
However, DDAH I appears to be the main isoform re-
sponsible for ADMA metabolism: DDAH I knockout mice
demonstrated significantly raised ADMA levels and systolic
blood pressure compared to wild types, despite DDAH II
expression remaining normal [19].
These studies suggest that DDAH manipulation may be a
useful tool in the treatment of cardiovascular disease.
3. Peripheral Arterial Disease (PAD)
In PAD, lower limb ischaemia results in intermittent clau-
dication: this describes pain in the aﬀected muscle groups
brought on by exercise and relieved by resting. In more
severe PAD, critical limb ischaemia (CLI) occurs: the patient
experiences chronic pain at rest, with blood flow to the limb
compromised to the extent that the aﬀected limb is at risk,
with development of ulcers and gangrene.
The Fontaine classification [20] stratifies these symptoms
to correlate with severity of the disease (Table 1).
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Table 1: Fontaine Classification: stages III and IV are also known as
CLI.
Stage I Asymptomatic
Stage II Intermittent claudication, no rest pain
IIa When walking a distance of greater than 200m
IIb When walking a distance of less than 200m
Stage III Nocturnal pain and/or pain at rest
Stage IV Tissue loss: ischaemic ulcers and/or gangrene
Current therapies for CLI centre on restoring blood
flow to the aﬀected limb by surgical and/or endovascular
procedures. Unfortunately, of all patients presenting with
CLI, only 50% will have disease amenable to revascularisa-
tion with 25% requiring a primary amputation. The overall
prognosis of these patients is also poor: within a year of
presentation, a quarter of the patients would have died, 30%
would have had a major amputation, and 20% continue to
suﬀer from CLI [1].
There is evidence that the NO-ADMA-DDAH pathway
plays an important role in PAD. Evidence of systemically
impaired NO synthesis has been described by Bo¨ger et al.
who showed urinary nitrate and cGMP excretion to diminish
in PAD patients as the disease progressed [2]. This group
also demonstrated that intravenous L-arginine administra-
tion induced NO-mediated vasodilation, increasing femoral
blood flow in patients with CLI, resulting in improved
walking distances and symptom scores [21]. Furthermore,
raised plasma ADMA levels have also been shown to correlate
with disease severity in PAD patients [5], implicating the
involvement of ADMA.
NO also promotes angiogenesis, activating vascular en-
dothelial growth factor and fibroblast growth factor [22].
Administration of NO antagonists to canine coronary
ischaemia models has demonstrated that NO is an important
mediator of new vessel growth [23]. This mechanism of
stimulation of new blood vessel development to supply
ischaemic tissue has been proposed as a possible treatment
for PAD, but clinical results have so far been disappointing.
The formation and persistence of new blood vessels is likely
to be multifactorial, involving a complex interaction between
chemokines and mechanical forces [24]. In addition, con-
tinued exposure to cardiovascular risk factors, such as
hypercholesterolaemia and hyperglycaemia, has been shown
to have a deleterious eﬀect on the NO pathway [25, 26].
However, the NO-ADMA-DDAH pathway role in PAD
is not confined to vascular dysfunction: NO-ADMA-DDAH
interaction is known to play significant parts in the function,
homeostasis, and repair of skeletal muscle.Weight for weight,
this is the most abundant tissue in the lower limb and
the majority of PAD symptoms are attributable to skeletal
muscle ischaemia; it can almost be regarded as a “target
organ” of PAD. Hence, the NO-ADMA-DDAH pathway
within ischaemic skeletal muscle represents a significant facet
of potential CLI therapy.
4. NO in Skeletal Muscle
Skeletal muscle has been shown to express both NOS I
and NOS III: NOS I is localized to the sarcolemma, and
NOS III associated with mitochondria and microvessels
within the tissue [27]. Within skeletal muscle, NO acts
as an endogenous modulator of vascular tone [28, 29],
neuromuscular transmission [30], muscle contraction [31,
32], muscle metabolism [27] and myogenesis [33]. Its role
in the regulation of muscle contraction is complex and
is influenced by the muscle fibre type and contraction
pattern and frequency involved [31]. NO has a number of
eﬀects on skeletal muscle metabolism [27]. It aﬀects glucose
metabolism, upregulating glucose uptake and inhibiting
glycolysis [34]; it has a direct inhibitory eﬀect on mitochon-
drial respiration [35]; and it antagonises creatinine kinase
activity, decreasing phosphocreatine breakdown, limiting
muscle function [36].
NO plays a role in myogenesis as well as repair and
regeneration following injury. It has been shown to mod-
ulate the inflammatory response to injured skeletal muscle,
controlling blood flow to the injured tissue, and aﬀecting
subsequent remodelling and repair [37]. In experimental
models of muscle crush injury, upregulation of local NO has
been demonstrated [38], inhibiting adhesion and inducing
apoptosis in inflammatory cells [39]. NOS is activated in
response to stretch in skeletal muscle, mediating the release
of hepatocyte growth factor and activatingmononuclear pro-
genitor cells called satellite cells (SC), which are responsible
for post-injury remodelling [40].
Tidball et al. showed that the addition of exogenous
NO upregulated the expression of structural proteins within
mouse myotubes and found that NOS antagonists inhibited
this, suggesting a regulatory role for NO in myogenesis [33].
In addition to local eﬀects, NO appears to play a part in
the systemic inflammatory response: experimental rats with
peritonitis or septic shock have been shown to have increased
expression of NOS in their skeletal muscle [41].
However, NO has also been shown to have deleterious
eﬀects, reacting with superoxide anions to form harmful
nitrogenous intermediates which are directly toxic to skeletal
muscle and inhibit mitochondrial function [41, 42].
5. NO in Ischaemia
Impaired NO-mediated vasodilation has been found in
postischaemic tissue such as myocardium [43], brain [44],
and skeletal muscle [45]. There is a complex interaction
between ischaemia and the NOS isoforms, with both up- and
downregulation reported in ischaemic models; for instance,
rat brain oxygen-glucose-deprivation models have shown
NOS II to be upregulated in response to ischaemia, which
in turn causes a downregulation of NOS I [46]; however,
ischaemic preconditioning of rat liver has been shown to
upregulate NOS III [47].
In skeletal muscle from patients with CLI, we have
previously found raised NOS III expression associated with
both microvessels within ischaemic muscle sections as well
as the muscle fibres themselves [48]. However, this was not
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Figure 2: ADMA/DDAH pathway in ischaemic muscle—preliminary data. (a) Western blot showing reduced DDAH2 expression in muscle
biopsies from patients with CLI. Lanes 1–4: control, 5–8: CLI muscle. (b) ELISA showing significantly higher ADMA levels in muscle from
patients with CLI (P = 0.03, Mann Whitney U test). (c) Western blot showing reduced DDAH2 expression in hypoxic myotubes (C: control,
H: hypoxia). (d) Conditioned medium from hypoxic C2C12 myotubes contained elevated levels of ADMA compared to medium from
myotubes cultured in normoxia. (P < 0.05, Student′s t-test). Medium from HMEC-1 cells was used as positive control.
associated with an increase in NOS activity. The involvement
of endogenous inhibitors may explain this and recent
preliminary data suggesting that ADMA levels in muscle
homogenates from patients with CLI are raised (Figures
2(a) and 2(b)). In addition, DDAH2 protein levels are also
upregulated in these ischaemic muscle biopsies.
To study the potential role of the ADMA/DDAH pathway
in skeletal muscle further, we evaluated their levels in my-
otubes cultured in ischaemic conditions in vitro. We found
reduced DDAH2 expression in ischaemic myotubes, whilst
ADMA levels were elevated in ischaemic myotube condi-
tioned media (Figures 2(c) and 2(d)).
Whilst the majority of studies have focussed on ADMA
associated with the vasculature/endothelial cells, our findings
from our in vitro studies suggest that ischaemic myotubes
may be a source of ADMA which can then act in a paracrine
fashion on surrounding endothelial cells or in an autocrine
manner on myotubes themselves with potentially detrimen-
tal eﬀects.
Fiedler et al. found that ADMA impairs vascular endo-
thelial growth factor (VEGF) mediated angiogenesis, and
that this was prevented by upregulation of DDAH [49].
Increased levels of ADMA produced by ischaemic muscle
may prevent angiogenesis in PAD patients and may be a
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factor in the failure of angiogenesis induction as a clinical
therapeutic approach.
6. Manipulation of the ADMA-DDAH Pathway
Control of NO levels by manipulating the ADMA-DDAH-
NO pathway represents a significant avenue for potential
early PAD treatment.
As L-arginine is the main precursor for NO production
(Figure 1), an increase in the availability of substrate ought
to result in an increase in NO. However, there is conflicting
evidence as to whether L-arginine supplementation has a
clinically significant benefit in cardiovascular disease: Sydow
and Mu¨nzel [50] showed that L-arginine improved radial
artery dilatation, in contrast to Walker et al’s findings
that vasodilatation was independent of oral L-arginine
supplementation [51]. In PAD, the Nitric Oxide in Peripheral
Arterial Insuﬃciency (NO-PAIN) study randomized 133
patients with intermittent claudication to oral L-arginine
versus placebo for 6 months. Whilst L-arginine supple-
mentation increased plasma L-arginine levels, there was no
improvement in NO availability or vascular function. This
was in contrast to earlier, smaller studies of shorter duration
demonstrating a beneficial eﬀect of L-arginine in PAD
patients [21]. A mechanism of “arginine-tolerance” was pro-
posed, in a similar manner to “nitrate-tolerance”, observed in
prolonged nitroglycerine use. More disappointingly, whilst
both groups in the NO-PAIN study showed improvement
in absolute walking distance, the improvement in the L-
arginine group was significantly less than the placebo group
[52].
An alternative strategy to increase NO levels may be
to reduce ADMA levels by enhancing DDAH activity or
expression. Nebivolol [53], pioglitazone [54], pravastatin
[55], and fenofibrate [56] have all been shown to decrease
ADMA by upregulating DDAH in vitro. Clinically, Sen et al.
demonstrated an increase in circulating NO and a decrease in
ADMA, coupled with improvement in symptoms in patients
with ischaemic heart disease treated with the selective beta1-
adrenergic receptor antagonist nebivolol [47]. Nishiyama et
al. found that the statin, pravastatin reduced serum ADMA
in patients with cerebrovascular disease [57].
In PAD, upregulation of DDAH at a local level to reduce
ADMA levels within the ischaemic muscle may be of benefit
in a number of ways: it may improve microvascular function
and local tissue perfusion; it may improve the results of
therapeutic angiogenesis by reducing the antiangiogenic
environment; or it may improve muscle contractile and
metabolic function and perhaps reduce tissue damage. In
patients with CLI, such strategies may be used as an adjunct
to improve the results of revascularisation techniques as well
as reduce tissue damage in patients with non-reconstructable
disease. They may also be of benefit to patients with earlier
disease to prevent disease progression.
7. Conclusion
There is considerable evidence that disruption of the NO
pathway plays a major role in the pathogenesis of PAD.
ADMA in particular, through its actions on NOS III, has
been shown to be an important modulator of NO. Early work
suggests that local or systemic manipulation of ADMA, by
upregulating DDAH, may prove to be a novel treatment for
PAD.
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